Please login to the form below

Not currently logged in
Email:
Password:

Dr Paula Salmikangas joins NDA Group

Moves to the regulatory affairs consultancy from the Finnish Medicines Agency

Paula SalmikaUK-headquartered regulatory affairs consultancy the NDA Group has appointed Dr Paula Salmikangas as a director.

She is the former chair of the EMA’s Committee for Advanced Therapies and comes to NDA from the Finnish Medicines Agency, where she served as a research professor.

She has also served as an adjunct professor of biochemistry for the University of Helsinki since 2006.

Dr Werner Van den Eynde, VP of NDA’s Advisory Board, said: “I am very excited to welcome Dr Paula Salmikangas on board. With her experience in and in-depth knowledge of biopharmaceuticals and advanced therapies she will be able to add tremendous value to clients in these areas and help them to make new and promising medicines available to patients.”

Dr Salmikangas is the second recent senior appointment at NDA Group following the appointment of Dr Van den Eynde, who joined earlier this month as its new vice president.

25th September 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics